Der Artikel von Brochstein ist sehr lesenswert. Für alle die zu faul sind den Link zu öffnen, ich poste einfach mal die wichtigsten Stellen als Zitate:
"General Cannabis (OTC: CANN) is one of the 26 cannabis-related companies I follow most closely at 420 Investor as part of my Focus List, and I continue to be cautious on the company’s near-term prospects due to my concerns about its weak results over the past two quarters as well as the existence of 6.8mm warrants with a weighted average exercise price of $0.64, a 65% discount to the current market price. I first shared this concern in November, when the stock was near $3.70. Though CANN has lost about half of its value since then, I remain cautious."
"To its credit, CANN files with the SEC, generates material revenue ($2.98mm in 2016) and has relatively good corporate governance for the sector, with its Board of Directors now having a majority of independent directors. …"
"General Cannabis financials have eroded. … The overall operating loss doubled to $2.187mm during Q1, with operations consuming $959K in cash."
"The balance sheet shows that the company ended Q1 with just $407K cash and current assets of $766K but current liabilities of $12.5mm, though most of this is “derivative liability” and not a cash obligation. General Cannabis ended the quarter with liabilities exceeding assets by over $12mm."
"Fortunately, CANN will likely see a cash infusion. In 2016, it borrowed $3mm at 12% and issued 9mm warrants in conjunction, with exercise prices split equally at $0.35 and $0.70. Through Q1, 6.86mm remained (average exercise price of $0.64), with an additional 300K exercised subsequent to the end of the quarter (at $0.5833). The full exercise of the remaining warrants will give the company approximately $4.2mm, which could help offset its debt and improve the balance sheet, though the sale will likely weigh on the stock price. 6.56mm shares represents 21% of the shares outstanding and a larger percentage of the float."
"I continue to suggest caution to my subscribers, suggesting the stock could fall to the $1.20-1.50 area, perhaps as low as $1.00 as the warrant issue plays out. On a fully-diluted basis, which takes into account all of the issued options (8.8mm with a weighted average exercise price of $1.09) and the warrants, there are about 35mm shares. At $1.50, the market cap would be about $52mm, which is very high based upon its current metrics like sales or book value, but the relative valuation to the rest of the sector would be reasonable at that level. Over the past six months, there has been substantial insider selling, though this appears to have abated."
Und CANCAN hier komm ich wieder und sage, du hast den letzten Teil neulich hier im Forum aus dem Zusammenhang gerissen und ziertet ohne den entscheidenden Nebensatz zu erwähnen, der alles in ein anderes Licht rückt! Denn der Autor merkt selber an, dass eine Marktkapitalisierung von 52 Mio. für die aktuellen zahlen schon sehr hoch wäre, auch wenn es relativ zum Sektor wieder passen würde. Diese Art der Meinungsmanipulation ist nicht fair allen anderen im Forum gegenüber.
Nur das Lesen der ganzen Quelle kann einem ein allumfassenden Bild geben. Also Leute nicht nur auf die Post hier vertrauen, sondern selber nach recherchieren und lesen. Es geht ja schließlich um euer Kapital!
Wie immer stellt alles von mir geäußerte keine Kauf- bzw. Verkaufsempfehlung dar.
PS: Da sich bisher nur CANMANN und ARTNER 514 zu Wort gemeldet haben, bin ich mir gar nicht mehr sicher wie der Rest des Forums mein sehr kritisches Reflektieren sieht!?!?!?! Aber ich sehe es als meine immanente Aufgabe an, Leute dazu zu animieren sich selber ein Bild zu machen und dann einen eigenen Standpunkt zu vertreten. Und ohne Multiperspektivität geht das nicht!
SAPERE AUDE |